nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP3A4—bone cancer	0.528	1	CbGaD
Fluvoxamine—CYP2B6—Cisplatin—bone cancer	0.0346	0.255	CbGbCtD
Fluvoxamine—CYP2B6—Doxorubicin—bone cancer	0.0232	0.171	CbGbCtD
Fluvoxamine—CYP2C9—Cisplatin—bone cancer	0.0183	0.135	CbGbCtD
Fluvoxamine—ABCB1—Cisplatin—bone cancer	0.0177	0.131	CbGbCtD
Fluvoxamine—ABCB1—Doxorubicin—bone cancer	0.0119	0.0877	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—bone cancer	0.0115	0.085	CbGbCtD
Fluvoxamine—CYP2D6—Doxorubicin—bone cancer	0.0112	0.0826	CbGbCtD
Fluvoxamine—CYP3A4—Doxorubicin—bone cancer	0.00711	0.0525	CbGbCtD
Fluvoxamine—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.00066	0.00797	CbGpPWpGaD
Fluvoxamine—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000657	0.00794	CbGpPWpGaD
Fluvoxamine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000656	0.00792	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000646	0.00781	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000645	0.00779	CbGpPWpGaD
Fluvoxamine—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000622	0.00751	CbGpPWpGaD
Fluvoxamine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000615	0.00743	CbGpPWpGaD
Fluvoxamine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000611	0.00738	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000609	0.00736	CbGpPWpGaD
Fluvoxamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000571	0.0069	CbGpPWpGaD
Fluvoxamine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000559	0.00675	CbGpPWpGaD
Fluvoxamine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000538	0.0065	CbGpPWpGaD
Fluvoxamine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000521	0.00629	CbGpPWpGaD
Fluvoxamine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000514	0.00621	CbGpPWpGaD
Fluvoxamine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00051	0.00616	CbGpPWpGaD
Fluvoxamine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000508	0.00614	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000499	0.00602	CbGpPWpGaD
Fluvoxamine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000497	0.006	CbGpPWpGaD
Fluvoxamine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000495	0.00597	CbGpPWpGaD
Fluvoxamine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00049	0.00592	CbGpPWpGaD
Fluvoxamine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000488	0.00589	CbGpPWpGaD
Fluvoxamine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000484	0.00585	CbGpPWpGaD
Fluvoxamine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000474	0.00573	CbGpPWpGaD
Fluvoxamine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000474	0.00573	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000459	0.00554	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000455	0.00549	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000454	0.00548	CbGpPWpGaD
Fluvoxamine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000436	0.00526	CbGpPWpGaD
Fluvoxamine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000419	0.00506	CbGpPWpGaD
Fluvoxamine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000416	0.00502	CbGpPWpGaD
Fluvoxamine—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00041	0.00495	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000389	0.00469	CbGpPWpGaD
Fluvoxamine—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000385	0.00465	CbGpPWpGaD
Fluvoxamine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000384	0.00464	CbGpPWpGaD
Fluvoxamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000377	0.00455	CbGpPWpGaD
Fluvoxamine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000375	0.00453	CbGpPWpGaD
Fluvoxamine—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000372	0.0045	CbGpPWpGaD
Fluvoxamine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000357	0.00431	CbGpPWpGaD
Fluvoxamine—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000351	0.00424	CbGpPWpGaD
Fluvoxamine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00035	0.00423	CbGpPWpGaD
Fluvoxamine—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000337	0.00407	CbGpPWpGaD
Fluvoxamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000334	0.00403	CbGpPWpGaD
Fluvoxamine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000307	0.00371	CbGpPWpGaD
Fluvoxamine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000303	0.00366	CbGpPWpGaD
Fluvoxamine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000301	0.00364	CbGpPWpGaD
Fluvoxamine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0003	0.00363	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.0003	0.00362	CbGpPWpGaD
Fluvoxamine—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000297	0.00359	CbGpPWpGaD
Fluvoxamine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000296	0.00358	CbGpPWpGaD
Fluvoxamine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000285	0.00344	CbGpPWpGaD
Fluvoxamine—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000284	0.00343	CbGpPWpGaD
Fluvoxamine—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00028	0.00338	CbGpPWpGaD
Fluvoxamine—SLC6A4—NRF2 pathway—GSTP1—bone cancer	0.000251	0.00304	CbGpPWpGaD
Fluvoxamine—SLC6A4—NRF2 pathway—TGFBR2—bone cancer	0.000251	0.00304	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—GNA11—bone cancer	0.000251	0.00303	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—EZH2—bone cancer	0.00025	0.00302	CbGpPWpGaD
Fluvoxamine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000249	0.00301	CbGpPWpGaD
Fluvoxamine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000246	0.00297	CbGpPWpGaD
Fluvoxamine—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000244	0.00295	CbGpPWpGaD
Fluvoxamine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000243	0.00294	CbGpPWpGaD
Fluvoxamine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000232	0.0028	CbGpPWpGaD
Fluvoxamine—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00023	0.00278	CbGpPWpGaD
Fluvoxamine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000229	0.00277	CbGpPWpGaD
Fluvoxamine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000224	0.0027	CbGpPWpGaD
Fluvoxamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000214	0.00258	CbGpPWpGaD
Fluvoxamine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000212	0.00256	CbGpPWpGaD
Fluvoxamine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000211	0.00255	CbGpPWpGaD
Fluvoxamine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000209	0.00252	CbGpPWpGaD
Fluvoxamine—Urethral disorder—Methotrexate—bone cancer	0.000208	0.000818	CcSEcCtD
Fluvoxamine—Weight decreased—Doxorubicin—bone cancer	0.000207	0.000817	CcSEcCtD
Fluvoxamine—Sinusitis—Epirubicin—bone cancer	0.000207	0.000816	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Doxorubicin—bone cancer	0.000207	0.000815	CcSEcCtD
Fluvoxamine—Agranulocytosis—Epirubicin—bone cancer	0.000206	0.000812	CcSEcCtD
Fluvoxamine—Pneumonia—Doxorubicin—bone cancer	0.000205	0.00081	CcSEcCtD
Fluvoxamine—Drowsiness—Doxorubicin—bone cancer	0.000204	0.000805	CcSEcCtD
Fluvoxamine—Visual impairment—Methotrexate—bone cancer	0.000204	0.000804	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000202	0.000798	CcSEcCtD
Fluvoxamine—Hypersensitivity—Cisplatin—bone cancer	0.000202	0.000796	CcSEcCtD
Fluvoxamine—Bradycardia—Epirubicin—bone cancer	0.000202	0.000795	CcSEcCtD
Fluvoxamine—Renal failure—Doxorubicin—bone cancer	0.000201	0.000792	CcSEcCtD
Fluvoxamine—Erythema multiforme—Methotrexate—bone cancer	0.0002	0.000789	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Doxorubicin—bone cancer	0.0002	0.000789	CcSEcCtD
Fluvoxamine—Haemoglobin—Epirubicin—bone cancer	0.000199	0.000785	CcSEcCtD
Fluvoxamine—Stomatitis—Doxorubicin—bone cancer	0.000199	0.000785	CcSEcCtD
Fluvoxamine—Jaundice—Doxorubicin—bone cancer	0.000199	0.000785	CcSEcCtD
Fluvoxamine—Rhinitis—Epirubicin—bone cancer	0.000199	0.000783	CcSEcCtD
Fluvoxamine—Conjunctivitis—Doxorubicin—bone cancer	0.000199	0.000783	CcSEcCtD
Fluvoxamine—Urinary tract infection—Doxorubicin—bone cancer	0.000199	0.000783	CcSEcCtD
Fluvoxamine—Haemorrhage—Epirubicin—bone cancer	0.000198	0.000781	CcSEcCtD
Fluvoxamine—Hepatitis—Epirubicin—bone cancer	0.000198	0.000781	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—bone cancer	0.000198	0.00078	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—bone cancer	0.000197	0.000778	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Epirubicin—bone cancer	0.000197	0.000777	CcSEcCtD
Fluvoxamine—Asthenia—Cisplatin—bone cancer	0.000197	0.000775	CcSEcCtD
Fluvoxamine—Pharyngitis—Epirubicin—bone cancer	0.000197	0.000775	CcSEcCtD
Fluvoxamine—Cardiac disorder—Methotrexate—bone cancer	0.000196	0.000775	CcSEcCtD
Fluvoxamine—Sweating—Doxorubicin—bone cancer	0.000196	0.000772	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Epirubicin—bone cancer	0.000196	0.000771	CcSEcCtD
Fluvoxamine—Oedema peripheral—Epirubicin—bone cancer	0.000195	0.00077	CcSEcCtD
Fluvoxamine—Haematuria—Doxorubicin—bone cancer	0.000195	0.000768	CcSEcCtD
Fluvoxamine—Urethral disorder—Epirubicin—bone cancer	0.000194	0.000766	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000193	0.000762	CcSEcCtD
Fluvoxamine—Epistaxis—Doxorubicin—bone cancer	0.000193	0.000759	CcSEcCtD
Fluvoxamine—Angiopathy—Methotrexate—bone cancer	0.000192	0.000757	CcSEcCtD
Fluvoxamine—Sinusitis—Doxorubicin—bone cancer	0.000192	0.000755	CcSEcCtD
Fluvoxamine—SLC6A3—NRF2 pathway—GSTP1—bone cancer	0.000191	0.00231	CbGpPWpGaD
Fluvoxamine—SLC6A3—NRF2 pathway—TGFBR2—bone cancer	0.000191	0.00231	CbGpPWpGaD
Fluvoxamine—Visual impairment—Epirubicin—bone cancer	0.000191	0.000753	CcSEcCtD
Fluvoxamine—Agranulocytosis—Doxorubicin—bone cancer	0.000191	0.000751	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—bone cancer	0.00019	0.000749	CcSEcCtD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000189	0.00229	CbGpPWpGaD
Fluvoxamine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000188	0.00227	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Cisplatin—bone cancer	0.000188	0.000739	CcSEcCtD
Fluvoxamine—Erythema multiforme—Epirubicin—bone cancer	0.000187	0.000739	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—bone cancer	0.000187	0.000738	CcSEcCtD
Fluvoxamine—Bradycardia—Doxorubicin—bone cancer	0.000187	0.000736	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—bone cancer	0.000185	0.000731	CcSEcCtD
Fluvoxamine—Eye disorder—Epirubicin—bone cancer	0.000185	0.00073	CcSEcCtD
Fluvoxamine—Tinnitus—Epirubicin—bone cancer	0.000185	0.000728	CcSEcCtD
Fluvoxamine—Malnutrition—Methotrexate—bone cancer	0.000184	0.000727	CcSEcCtD
Fluvoxamine—Haemoglobin—Doxorubicin—bone cancer	0.000184	0.000727	CcSEcCtD
Fluvoxamine—Cardiac disorder—Epirubicin—bone cancer	0.000184	0.000725	CcSEcCtD
Fluvoxamine—Rhinitis—Doxorubicin—bone cancer	0.000184	0.000725	CcSEcCtD
Fluvoxamine—Haemorrhage—Doxorubicin—bone cancer	0.000183	0.000723	CcSEcCtD
Fluvoxamine—Hepatitis—Doxorubicin—bone cancer	0.000183	0.000723	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Doxorubicin—bone cancer	0.000182	0.000719	CcSEcCtD
Fluvoxamine—Pharyngitis—Doxorubicin—bone cancer	0.000182	0.000717	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Doxorubicin—bone cancer	0.000181	0.000714	CcSEcCtD
Fluvoxamine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000181	0.00219	CbGpPWpGaD
Fluvoxamine—Oedema peripheral—Doxorubicin—bone cancer	0.000181	0.000712	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—bone cancer	0.00018	0.000712	CcSEcCtD
Fluvoxamine—Angiopathy—Epirubicin—bone cancer	0.00018	0.000709	CcSEcCtD
Fluvoxamine—Urethral disorder—Doxorubicin—bone cancer	0.00018	0.000709	CcSEcCtD
Fluvoxamine—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000179	0.00216	CbGpPWpGaD
Fluvoxamine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000179	0.00216	CbGpPWpGaD
Fluvoxamine—Back pain—Methotrexate—bone cancer	0.000178	0.000703	CcSEcCtD
Fluvoxamine—Chills—Epirubicin—bone cancer	0.000178	0.000701	CcSEcCtD
Fluvoxamine—Arrhythmia—Epirubicin—bone cancer	0.000177	0.000698	CcSEcCtD
Fluvoxamine—Visual impairment—Doxorubicin—bone cancer	0.000177	0.000697	CcSEcCtD
Fluvoxamine—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000176	0.00213	CbGpPWpGaD
Fluvoxamine—Alopecia—Epirubicin—bone cancer	0.000175	0.00069	CcSEcCtD
Fluvoxamine—Vomiting—Cisplatin—bone cancer	0.000174	0.000687	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—bone cancer	0.000174	0.000685	CcSEcCtD
Fluvoxamine—Mental disorder—Epirubicin—bone cancer	0.000174	0.000684	CcSEcCtD
Fluvoxamine—Erythema multiforme—Doxorubicin—bone cancer	0.000173	0.000683	CcSEcCtD
Fluvoxamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000173	0.00209	CbGpPWpGaD
Fluvoxamine—Rash—Cisplatin—bone cancer	0.000173	0.000681	CcSEcCtD
Fluvoxamine—Dermatitis—Cisplatin—bone cancer	0.000173	0.000681	CcSEcCtD
Fluvoxamine—Malnutrition—Epirubicin—bone cancer	0.000172	0.00068	CcSEcCtD
Fluvoxamine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000172	0.00207	CbGpPWpGaD
Fluvoxamine—Eye disorder—Doxorubicin—bone cancer	0.000171	0.000676	CcSEcCtD
Fluvoxamine—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000171	0.00207	CbGpPWpGaD
Fluvoxamine—Ill-defined disorder—Methotrexate—bone cancer	0.000171	0.000674	CcSEcCtD
Fluvoxamine—Tinnitus—Doxorubicin—bone cancer	0.000171	0.000674	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—bone cancer	0.00017	0.000672	CcSEcCtD
Fluvoxamine—Cardiac disorder—Doxorubicin—bone cancer	0.00017	0.000671	CcSEcCtD
Fluvoxamine—Flatulence—Epirubicin—bone cancer	0.00017	0.00067	CcSEcCtD
Fluvoxamine—Tension—Epirubicin—bone cancer	0.000169	0.000667	CcSEcCtD
Fluvoxamine—Dysgeusia—Epirubicin—bone cancer	0.000169	0.000666	CcSEcCtD
Fluvoxamine—Nervousness—Epirubicin—bone cancer	0.000168	0.000661	CcSEcCtD
Fluvoxamine—Back pain—Epirubicin—bone cancer	0.000167	0.000658	CcSEcCtD
Fluvoxamine—Angiopathy—Doxorubicin—bone cancer	0.000166	0.000656	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—bone cancer	0.000166	0.000655	CcSEcCtD
Fluvoxamine—Muscle spasms—Epirubicin—bone cancer	0.000166	0.000654	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—bone cancer	0.000166	0.000653	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—bone cancer	0.000165	0.00065	CcSEcCtD
Fluvoxamine—Chills—Doxorubicin—bone cancer	0.000165	0.000649	CcSEcCtD
Fluvoxamine—Arrhythmia—Doxorubicin—bone cancer	0.000164	0.000646	CcSEcCtD
Fluvoxamine—Nausea—Cisplatin—bone cancer	0.000163	0.000642	CcSEcCtD
Fluvoxamine—Vision blurred—Epirubicin—bone cancer	0.000163	0.000641	CcSEcCtD
Fluvoxamine—Alopecia—Doxorubicin—bone cancer	0.000162	0.000639	CcSEcCtD
Fluvoxamine—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.000161	0.00195	CbGpPWpGaD
Fluvoxamine—Cough—Methotrexate—bone cancer	0.000161	0.000634	CcSEcCtD
Fluvoxamine—Mental disorder—Doxorubicin—bone cancer	0.000161	0.000633	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Epirubicin—bone cancer	0.00016	0.000631	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—bone cancer	0.00016	0.00063	CcSEcCtD
Fluvoxamine—Malnutrition—Doxorubicin—bone cancer	0.00016	0.000629	CcSEcCtD
Fluvoxamine—Anaemia—Epirubicin—bone cancer	0.000159	0.000629	CcSEcCtD
Fluvoxamine—Agitation—Epirubicin—bone cancer	0.000159	0.000625	CcSEcCtD
Fluvoxamine—Flatulence—Doxorubicin—bone cancer	0.000157	0.00062	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—bone cancer	0.000157	0.000619	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—bone cancer	0.000157	0.000619	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—bone cancer	0.000157	0.000619	CcSEcCtD
Fluvoxamine—Tension—Doxorubicin—bone cancer	0.000157	0.000617	CcSEcCtD
Fluvoxamine—Dysgeusia—Doxorubicin—bone cancer	0.000156	0.000616	CcSEcCtD
Fluvoxamine—Malaise—Epirubicin—bone cancer	0.000156	0.000613	CcSEcCtD
Fluvoxamine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000156	0.00188	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000156	0.00188	CbGpPWpGaD
Fluvoxamine—Discomfort—Methotrexate—bone cancer	0.000155	0.000611	CcSEcCtD
Fluvoxamine—Nervousness—Doxorubicin—bone cancer	0.000155	0.000611	CcSEcCtD
Fluvoxamine—Vertigo—Epirubicin—bone cancer	0.000155	0.000611	CcSEcCtD
Fluvoxamine—Syncope—Epirubicin—bone cancer	0.000155	0.00061	CcSEcCtD
Fluvoxamine—Leukopenia—Epirubicin—bone cancer	0.000154	0.000609	CcSEcCtD
Fluvoxamine—Back pain—Doxorubicin—bone cancer	0.000154	0.000609	CcSEcCtD
Fluvoxamine—Muscle spasms—Doxorubicin—bone cancer	0.000153	0.000605	CcSEcCtD
Fluvoxamine—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000153	0.00185	CbGpPWpGaD
Fluvoxamine—Palpitations—Epirubicin—bone cancer	0.000152	0.000601	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—bone cancer	0.000152	0.000598	CcSEcCtD
Fluvoxamine—Loss of consciousness—Epirubicin—bone cancer	0.000152	0.000598	CcSEcCtD
Fluvoxamine—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000151	0.00182	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000151	0.00182	CbGpPWpGaD
Fluvoxamine—Cough—Epirubicin—bone cancer	0.000151	0.000593	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—bone cancer	0.00015	0.000593	CcSEcCtD
Fluvoxamine—Vision blurred—Doxorubicin—bone cancer	0.00015	0.000593	CcSEcCtD
Fluvoxamine—Convulsion—Epirubicin—bone cancer	0.000149	0.000589	CcSEcCtD
Fluvoxamine—Infection—Methotrexate—bone cancer	0.000149	0.000589	CcSEcCtD
Fluvoxamine—Hypertension—Epirubicin—bone cancer	0.000149	0.000587	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Doxorubicin—bone cancer	0.000148	0.000584	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—bone cancer	0.000148	0.000582	CcSEcCtD
Fluvoxamine—Anaemia—Doxorubicin—bone cancer	0.000148	0.000582	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—bone cancer	0.000147	0.000581	CcSEcCtD
Fluvoxamine—Arthralgia—Epirubicin—bone cancer	0.000147	0.000579	CcSEcCtD
Fluvoxamine—Chest pain—Epirubicin—bone cancer	0.000147	0.000579	CcSEcCtD
Fluvoxamine—Myalgia—Epirubicin—bone cancer	0.000147	0.000579	CcSEcCtD
Fluvoxamine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000147	0.00177	CbGpPWpGaD
Fluvoxamine—Agitation—Doxorubicin—bone cancer	0.000147	0.000578	CcSEcCtD
Fluvoxamine—Anxiety—Epirubicin—bone cancer	0.000146	0.000577	CcSEcCtD
Fluvoxamine—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000145	0.00176	CbGpPWpGaD
Fluvoxamine—Hyperhidrosis—Methotrexate—bone cancer	0.000145	0.000573	CcSEcCtD
Fluvoxamine—Discomfort—Epirubicin—bone cancer	0.000145	0.000572	CcSEcCtD
Fluvoxamine—Malaise—Doxorubicin—bone cancer	0.000144	0.000567	CcSEcCtD
Fluvoxamine—Dry mouth—Epirubicin—bone cancer	0.000144	0.000566	CcSEcCtD
Fluvoxamine—Vertigo—Doxorubicin—bone cancer	0.000143	0.000565	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—bone cancer	0.000143	0.000565	CcSEcCtD
Fluvoxamine—Syncope—Doxorubicin—bone cancer	0.000143	0.000564	CcSEcCtD
Fluvoxamine—Leukopenia—Doxorubicin—bone cancer	0.000143	0.000563	CcSEcCtD
Fluvoxamine—Confusional state—Epirubicin—bone cancer	0.000142	0.00056	CcSEcCtD
Fluvoxamine—SLC6A4—Circadian rythm related genes—CDK4—bone cancer	0.000141	0.0017	CbGpPWpGaD
Fluvoxamine—Palpitations—Doxorubicin—bone cancer	0.000141	0.000556	CcSEcCtD
Fluvoxamine—Oedema—Epirubicin—bone cancer	0.000141	0.000555	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Epirubicin—bone cancer	0.000141	0.000555	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—bone cancer	0.000141	0.000554	CcSEcCtD
Fluvoxamine—Loss of consciousness—Doxorubicin—bone cancer	0.00014	0.000553	CcSEcCtD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00014	0.00169	CbGpPWpGaD
Fluvoxamine—Infection—Epirubicin—bone cancer	0.00014	0.000551	CcSEcCtD
Fluvoxamine—Cough—Doxorubicin—bone cancer	0.000139	0.000549	CcSEcCtD
Fluvoxamine—Shock—Epirubicin—bone cancer	0.000138	0.000546	CcSEcCtD
Fluvoxamine—Convulsion—Doxorubicin—bone cancer	0.000138	0.000545	CcSEcCtD
Fluvoxamine—Nervous system disorder—Epirubicin—bone cancer	0.000138	0.000544	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Epirubicin—bone cancer	0.000138	0.000543	CcSEcCtD
Fluvoxamine—Hypertension—Doxorubicin—bone cancer	0.000138	0.000543	CcSEcCtD
Fluvoxamine—Tachycardia—Epirubicin—bone cancer	0.000137	0.000542	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000137	0.00054	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Epirubicin—bone cancer	0.000136	0.000537	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—bone cancer	0.000136	0.000536	CcSEcCtD
Fluvoxamine—Myalgia—Doxorubicin—bone cancer	0.000136	0.000536	CcSEcCtD
Fluvoxamine—Chest pain—Doxorubicin—bone cancer	0.000136	0.000536	CcSEcCtD
Fluvoxamine—Arthralgia—Doxorubicin—bone cancer	0.000136	0.000536	CcSEcCtD
Fluvoxamine—Anxiety—Doxorubicin—bone cancer	0.000135	0.000534	CcSEcCtD
Fluvoxamine—Paraesthesia—Methotrexate—bone cancer	0.000135	0.000533	CcSEcCtD
Fluvoxamine—Discomfort—Doxorubicin—bone cancer	0.000134	0.000529	CcSEcCtD
Fluvoxamine—Anorexia—Epirubicin—bone cancer	0.000134	0.000529	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—bone cancer	0.000134	0.000529	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—bone cancer	0.000134	0.000527	CcSEcCtD
Fluvoxamine—Dry mouth—Doxorubicin—bone cancer	0.000133	0.000524	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—bone cancer	0.000132	0.000522	CcSEcCtD
Fluvoxamine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000132	0.0016	CbGpPWpGaD
Fluvoxamine—Hypotension—Epirubicin—bone cancer	0.000132	0.000519	CcSEcCtD
Fluvoxamine—Confusional state—Doxorubicin—bone cancer	0.000131	0.000518	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—bone cancer	0.000131	0.000516	CcSEcCtD
Fluvoxamine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000131	0.00158	CbGpPWpGaD
Fluvoxamine—Oedema—Doxorubicin—bone cancer	0.00013	0.000514	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Doxorubicin—bone cancer	0.00013	0.000514	CcSEcCtD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00013	0.00157	CbGpPWpGaD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00013	0.000512	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—bone cancer	0.00013	0.000511	CcSEcCtD
Fluvoxamine—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.00013	0.00157	CbGpPWpGaD
Fluvoxamine—Infection—Doxorubicin—bone cancer	0.000129	0.00051	CcSEcCtD
Fluvoxamine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000129	0.00156	CbGpPWpGaD
Fluvoxamine—Pain—Methotrexate—bone cancer	0.000129	0.000507	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000128	0.000506	CcSEcCtD
Fluvoxamine—Shock—Doxorubicin—bone cancer	0.000128	0.000505	CcSEcCtD
Fluvoxamine—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000128	0.00154	CbGpPWpGaD
Fluvoxamine—Nervous system disorder—Doxorubicin—bone cancer	0.000128	0.000504	CcSEcCtD
Fluvoxamine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000128	0.00154	CbGpPWpGaD
Fluvoxamine—Thrombocytopenia—Doxorubicin—bone cancer	0.000128	0.000503	CcSEcCtD
Fluvoxamine—Insomnia—Epirubicin—bone cancer	0.000127	0.000502	CcSEcCtD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000127	0.00154	CbGpPWpGaD
Fluvoxamine—Tachycardia—Doxorubicin—bone cancer	0.000127	0.000501	CcSEcCtD
Fluvoxamine—Paraesthesia—Epirubicin—bone cancer	0.000126	0.000498	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Doxorubicin—bone cancer	0.000126	0.000496	CcSEcCtD
Fluvoxamine—Dyspnoea—Epirubicin—bone cancer	0.000126	0.000495	CcSEcCtD
Fluvoxamine—Somnolence—Epirubicin—bone cancer	0.000125	0.000493	CcSEcCtD
Fluvoxamine—Anorexia—Doxorubicin—bone cancer	0.000124	0.00049	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—bone cancer	0.000124	0.000489	CcSEcCtD
Fluvoxamine—Dyspepsia—Epirubicin—bone cancer	0.000124	0.000489	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—bone cancer	0.000123	0.000485	CcSEcCtD
Fluvoxamine—Decreased appetite—Epirubicin—bone cancer	0.000122	0.000482	CcSEcCtD
Fluvoxamine—CYP1A1—Biological oxidations—CYP3A4—bone cancer	0.000122	0.00148	CbGpPWpGaD
Fluvoxamine—Hypotension—Doxorubicin—bone cancer	0.000122	0.00048	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000122	0.000479	CcSEcCtD
Fluvoxamine—Fatigue—Epirubicin—bone cancer	0.000121	0.000479	CcSEcCtD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000121	0.00146	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000121	0.00146	CbGpPWpGaD
Fluvoxamine—Pain—Epirubicin—bone cancer	0.00012	0.000475	CcSEcCtD
Fluvoxamine—Constipation—Epirubicin—bone cancer	0.00012	0.000475	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—bone cancer	0.000119	0.000471	CcSEcCtD
Fluvoxamine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000119	0.00144	CbGpPWpGaD
Fluvoxamine—Body temperature increased—Methotrexate—bone cancer	0.000119	0.000469	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—bone cancer	0.000119	0.000469	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000119	0.000468	CcSEcCtD
Fluvoxamine—Insomnia—Doxorubicin—bone cancer	0.000118	0.000464	CcSEcCtD
Fluvoxamine—Paraesthesia—Doxorubicin—bone cancer	0.000117	0.000461	CcSEcCtD
Fluvoxamine—Dyspnoea—Doxorubicin—bone cancer	0.000116	0.000458	CcSEcCtD
Fluvoxamine—Feeling abnormal—Epirubicin—bone cancer	0.000116	0.000457	CcSEcCtD
Fluvoxamine—Somnolence—Doxorubicin—bone cancer	0.000116	0.000457	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Epirubicin—bone cancer	0.000115	0.000454	CcSEcCtD
Fluvoxamine—Dyspepsia—Doxorubicin—bone cancer	0.000115	0.000452	CcSEcCtD
Fluvoxamine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000114	0.00138	CbGpPWpGaD
Fluvoxamine—Decreased appetite—Doxorubicin—bone cancer	0.000113	0.000446	CcSEcCtD
Fluvoxamine—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000113	0.00137	CbGpPWpGaD
Fluvoxamine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000112	0.000443	CcSEcCtD
Fluvoxamine—Fatigue—Doxorubicin—bone cancer	0.000112	0.000443	CcSEcCtD
Fluvoxamine—Urticaria—Epirubicin—bone cancer	0.000112	0.000441	CcSEcCtD
Fluvoxamine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000112	0.00135	CbGpPWpGaD
Fluvoxamine—Pain—Doxorubicin—bone cancer	0.000111	0.000439	CcSEcCtD
Fluvoxamine—Constipation—Doxorubicin—bone cancer	0.000111	0.000439	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—JUN—bone cancer	0.000111	0.00134	CbGpPWpGaD
Fluvoxamine—Abdominal pain—Epirubicin—bone cancer	0.000111	0.000439	CcSEcCtD
Fluvoxamine—Body temperature increased—Epirubicin—bone cancer	0.000111	0.000439	CcSEcCtD
Fluvoxamine—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000111	0.00134	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Methotrexate—bone cancer	0.000111	0.000437	CcSEcCtD
Fluvoxamine—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000111	0.00134	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00011	0.00133	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00011	0.00133	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000109	0.00132	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000109	0.00132	CbGpPWpGaD
Fluvoxamine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000109	0.00131	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000108	0.00131	CbGpPWpGaD
Fluvoxamine—Asthenia—Methotrexate—bone cancer	0.000108	0.000426	CcSEcCtD
Fluvoxamine—Feeling abnormal—Doxorubicin—bone cancer	0.000107	0.000423	CcSEcCtD
Fluvoxamine—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000107	0.0013	CbGpPWpGaD
Fluvoxamine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000107	0.00042	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—bone cancer	0.000106	0.00042	CcSEcCtD
Fluvoxamine—CYP1A1—Biological oxidations—GSTP1—bone cancer	0.000105	0.00126	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Epirubicin—bone cancer	0.000104	0.000409	CcSEcCtD
Fluvoxamine—Urticaria—Doxorubicin—bone cancer	0.000103	0.000408	CcSEcCtD
Fluvoxamine—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000103	0.00124	CbGpPWpGaD
Fluvoxamine—Body temperature increased—Doxorubicin—bone cancer	0.000103	0.000406	CcSEcCtD
Fluvoxamine—Abdominal pain—Doxorubicin—bone cancer	0.000103	0.000406	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—bone cancer	0.000103	0.000406	CcSEcCtD
Fluvoxamine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000103	0.00124	CbGpPWpGaD
Fluvoxamine—Asthenia—Epirubicin—bone cancer	0.000101	0.000398	CcSEcCtD
Fluvoxamine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.0001	0.00121	CbGpPWpGaD
Fluvoxamine—Pruritus—Epirubicin—bone cancer	9.96e-05	0.000393	CcSEcCtD
Fluvoxamine—Dizziness—Methotrexate—bone cancer	9.95e-05	0.000392	CcSEcCtD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	9.92e-05	0.0012	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	9.86e-05	0.00119	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	9.86e-05	0.00119	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Epirubicin—bone cancer	9.63e-05	0.00038	CcSEcCtD
Fluvoxamine—Hypersensitivity—Doxorubicin—bone cancer	9.6e-05	0.000378	CcSEcCtD
Fluvoxamine—Vomiting—Methotrexate—bone cancer	9.56e-05	0.000377	CcSEcCtD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—BRAF—bone cancer	9.55e-05	0.00115	CbGpPWpGaD
Fluvoxamine—Rash—Methotrexate—bone cancer	9.48e-05	0.000374	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—bone cancer	9.48e-05	0.000374	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—bone cancer	9.42e-05	0.000372	CcSEcCtD
Fluvoxamine—Asthenia—Doxorubicin—bone cancer	9.35e-05	0.000368	CcSEcCtD
Fluvoxamine—Dizziness—Epirubicin—bone cancer	9.31e-05	0.000367	CcSEcCtD
Fluvoxamine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	9.28e-05	0.00112	CbGpPWpGaD
Fluvoxamine—Pruritus—Doxorubicin—bone cancer	9.22e-05	0.000363	CcSEcCtD
Fluvoxamine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	9.2e-05	0.00111	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	9.12e-05	0.0011	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—JUN—bone cancer	9.09e-05	0.0011	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	9.07e-05	0.0011	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.99e-05	0.00109	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	8.98e-05	0.00108	CbGpPWpGaD
Fluvoxamine—Vomiting—Epirubicin—bone cancer	8.95e-05	0.000353	CcSEcCtD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	8.94e-05	0.00108	CbGpPWpGaD
Fluvoxamine—Nausea—Methotrexate—bone cancer	8.93e-05	0.000352	CcSEcCtD
Fluvoxamine—Diarrhoea—Doxorubicin—bone cancer	8.91e-05	0.000351	CcSEcCtD
Fluvoxamine—CYP3A7—Metabolism—NT5C3A—bone cancer	8.89e-05	0.00107	CbGpPWpGaD
Fluvoxamine—Rash—Epirubicin—bone cancer	8.88e-05	0.00035	CcSEcCtD
Fluvoxamine—Dermatitis—Epirubicin—bone cancer	8.87e-05	0.00035	CcSEcCtD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	8.85e-05	0.00107	CbGpPWpGaD
Fluvoxamine—Headache—Epirubicin—bone cancer	8.82e-05	0.000348	CcSEcCtD
Fluvoxamine—Dizziness—Doxorubicin—bone cancer	8.61e-05	0.00034	CcSEcCtD
Fluvoxamine—CYP2C19—Biological oxidations—GSTP1—bone cancer	8.55e-05	0.00103	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	8.43e-05	0.00102	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	8.39e-05	0.00101	CbGpPWpGaD
Fluvoxamine—Nausea—Epirubicin—bone cancer	8.36e-05	0.00033	CcSEcCtD
Fluvoxamine—Vomiting—Doxorubicin—bone cancer	8.28e-05	0.000327	CcSEcCtD
Fluvoxamine—Rash—Doxorubicin—bone cancer	8.21e-05	0.000324	CcSEcCtD
Fluvoxamine—Dermatitis—Doxorubicin—bone cancer	8.2e-05	0.000323	CcSEcCtD
Fluvoxamine—Headache—Doxorubicin—bone cancer	8.16e-05	0.000322	CcSEcCtD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—MDM2—bone cancer	8e-05	0.000966	CbGpPWpGaD
Fluvoxamine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.94e-05	0.000959	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—NDUFA12—bone cancer	7.93e-05	0.000958	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—GSTP1—bone cancer	7.87e-05	0.00095	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.8e-05	0.000942	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	7.79e-05	0.000941	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NDUFA12—bone cancer	7.77e-05	0.000938	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	7.76e-05	0.000937	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NDUFA12—bone cancer	7.75e-05	0.000936	CbGpPWpGaD
Fluvoxamine—Nausea—Doxorubicin—bone cancer	7.74e-05	0.000305	CcSEcCtD
Fluvoxamine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.69e-05	0.000929	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	7.68e-05	0.000928	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	7.5e-05	0.000906	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.48e-05	0.000904	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NDUFA12—bone cancer	7.32e-05	0.000885	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—BRAF—bone cancer	7.31e-05	0.000883	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	7.03e-05	0.000849	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.03e-05	0.000849	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—GSTP1—bone cancer	6.66e-05	0.000805	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—NT5C3A—bone cancer	6.57e-05	0.000794	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	6.57e-05	0.000794	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.46e-05	0.00078	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NT5C3A—bone cancer	6.44e-05	0.000777	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NT5C3A—bone cancer	6.42e-05	0.000776	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—MDM2—bone cancer	6.13e-05	0.00074	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NT5C3A—bone cancer	6.07e-05	0.000733	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—TP53—bone cancer	6e-05	0.000725	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NDUFA12—bone cancer	5.99e-05	0.000724	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NDUFA12—bone cancer	5.85e-05	0.000707	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.56e-05	0.000672	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NDUFA12—bone cancer	5.51e-05	0.000666	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NDUFA12—bone cancer	5.47e-05	0.00066	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.14e-05	0.000621	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.07e-05	0.000613	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NT5C3A—bone cancer	4.97e-05	0.0006	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NT5C3A—bone cancer	4.85e-05	0.000585	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NDUFA12—bone cancer	4.67e-05	0.000564	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NT5C3A—bone cancer	4.57e-05	0.000552	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NT5C3A—bone cancer	4.53e-05	0.000547	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.13e-05	0.000498	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.98e-05	0.00048	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ENO2—bone cancer	3.89e-05	0.00047	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NT5C3A—bone cancer	3.87e-05	0.000467	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—DHFR—bone cancer	3.61e-05	0.000436	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NDUFA12—bone cancer	3.6e-05	0.000435	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.59e-05	0.000433	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GNA11—bone cancer	3.38e-05	0.000408	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CYP3A4—bone cancer	3.06e-05	0.00037	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NT5C3A—bone cancer	2.99e-05	0.000361	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ENO2—bone cancer	2.88e-05	0.000348	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ENO2—bone cancer	2.82e-05	0.000341	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.82e-05	0.00034	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ENO2—bone cancer	2.81e-05	0.00034	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—DHFR—bone cancer	2.67e-05	0.000323	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ENO2—bone cancer	2.66e-05	0.000321	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSTP1—bone cancer	2.62e-05	0.000316	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—DHFR—bone cancer	2.62e-05	0.000316	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—DHFR—bone cancer	2.61e-05	0.000315	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GNA11—bone cancer	2.5e-05	0.000301	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—DHFR—bone cancer	2.47e-05	0.000298	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GNA11—bone cancer	2.44e-05	0.000295	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GNA11—bone cancer	2.44e-05	0.000295	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.37e-05	0.000286	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GNA11—bone cancer	2.31e-05	0.000278	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP3A4—bone cancer	2.26e-05	0.000273	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP3A4—bone cancer	2.22e-05	0.000268	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP3A4—bone cancer	2.21e-05	0.000267	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ENO2—bone cancer	2.18e-05	0.000263	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ENO2—bone cancer	2.12e-05	0.000256	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP3A4—bone cancer	2.09e-05	0.000252	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.08e-05	0.000251	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—DHFR—bone cancer	2.02e-05	0.000244	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ENO2—bone cancer	2e-05	0.000242	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ENO2—bone cancer	1.98e-05	0.00024	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—DHFR—bone cancer	1.97e-05	0.000238	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTP1—bone cancer	1.94e-05	0.000234	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTP1—bone cancer	1.9e-05	0.000229	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTP1—bone cancer	1.89e-05	0.000228	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GNA11—bone cancer	1.89e-05	0.000228	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—DHFR—bone cancer	1.86e-05	0.000224	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GNA11—bone cancer	1.84e-05	0.000222	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—DHFR—bone cancer	1.84e-05	0.000222	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTP1—bone cancer	1.79e-05	0.000216	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GNA11—bone cancer	1.73e-05	0.00021	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GNA11—bone cancer	1.72e-05	0.000208	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.71e-05	0.000207	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.7e-05	0.000205	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ENO2—bone cancer	1.7e-05	0.000205	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP3A4—bone cancer	1.67e-05	0.000202	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.57e-05	0.00019	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—DHFR—bone cancer	1.57e-05	0.00019	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.56e-05	0.000188	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.55e-05	0.000187	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GNA11—bone cancer	1.47e-05	0.000178	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTP1—bone cancer	1.46e-05	0.000177	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTP1—bone cancer	1.43e-05	0.000172	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTGS2—bone cancer	1.36e-05	0.000164	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTP1—bone cancer	1.35e-05	0.000162	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTP1—bone cancer	1.33e-05	0.000161	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.33e-05	0.000161	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.33e-05	0.00016	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ENO2—bone cancer	1.31e-05	0.000158	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—DHFR—bone cancer	1.21e-05	0.000147	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTP1—bone cancer	1.14e-05	0.000138	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GNA11—bone cancer	1.13e-05	0.000137	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTGS2—bone cancer	1e-05	0.000121	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTGS2—bone cancer	9.82e-06	0.000119	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTGS2—bone cancer	9.8e-06	0.000118	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTGS2—bone cancer	9.26e-06	0.000112	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTP1—bone cancer	8.8e-06	0.000106	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTGS2—bone cancer	7.58e-06	9.15e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTGS2—bone cancer	7.4e-06	8.93e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTGS2—bone cancer	6.97e-06	8.42e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTGS2—bone cancer	6.91e-06	8.34e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTGS2—bone cancer	5.9e-06	7.13e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTGS2—bone cancer	4.56e-06	5.5e-05	CbGpPWpGaD
